PMID- 32237429
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20200625
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 45
IP  - 1
DP  - 2020 Jan
TI  - [Meta-analysis of effect of Jinqi Jiangtang Tablets on treating insulin 
      resistance in type 2 diabetes].
PG  - 188-195
LID - 10.19540/j.cnki.cjcmm.20190401.502 [doi]
AB  - To systematically assess the efficacy and safety of Jinqi Jiangtang Tablets for 
      patients with insulin resistance in type 2 diabetes, literatures were retrieved 
      in 7 databases: PubMed, EMbase, Cochrane Library, Chinese National Knowledge 
      Infrastructure(CNKI), WanFang database, Chinese BioMedical Database(CBM), VIP 
      Chinese Science and Technique Journals Database, from the date of its inception 
      up to November 2018. Review Manager 5.3 software was used for risk bias 
      assessment, data synthesis and subgroup analysis. Begg's and Egger's tests were 
      performed for assessing symmetries of funnel plot by software Stata 14.0. GRADE 
      system was used to assess the quality of evidence. A total of 10 trials involving 
      797 participants were eligible. Compared with Western medicine alone, Jinqi 
      Jiangtang Tablets showed a statistical significance in FBG(WMD=-0.63, 
      95%CI[-1.00,-0.26]). Jinqi Jiangtang Tablets showed a significant decrease in 2 h 
      BG combined with Western medicine compared with Western medicine alone(WMD=-1.46, 
      95%CI[-1.71,-1.21], P<0.000 01). Jinqi Jiangtang Tablets combined with Western 
      medicine showed a significant decrease in HbA1 c(WMD=-0.75, 95%CI[-0.97,-0.53], 
      P<0.000 01), FINS(WMD=-0.65, 95%CI[-0.80,-0.50], P<0.000 01), 2 h 
      INS(SMD=-1.67, 95%CI[-2.26,-1.09], P<0.000 01) and HOMA-IR(WMD=-1.22, 
      95%CI[-1.67,-0.76], P<0.000 01). Jinqi Jiangtang Tablets combined with Western 
      medicine was beneficial for ISI(WMD=1.00, 95%CI[0.84, 1.17], P<0.000 01). 
      Egger's and Begg's test showed no publication bias(P=0.379). Sensitivity analysis 
      showed no impact on the overall results. The GRADE quality of the evidence was 
      low. Despite of the apparently positive results, we cannot draw a rational 
      conclusion that Jinqi Jiangtang Tablets has a positive effect in patients with 
      IR, because of the low evidence grade.
FAU - Deng, Zhi-Yuan
AU  - Deng ZY
AD  - the First Clinical College, Guangzhou University of Chinese Medicine Guangzhou 
      510405, China.
FAU - Wang, Man-Jia
AU  - Wang MJ
AD  - the First Clinical College, Guangzhou University of Chinese Medicine Guangzhou 
      510405, China.
FAU - Fan, Yao-Hua
AU  - Fan YH
AD  - the First Clinical College, Guangzhou University of Chinese Medicine Guangzhou 
      510405, China.
FAU - Liu, Min
AU  - Liu M
AD  - the First Affiliated Hospital, Guangzhou University of Chinese Medicine Guangzhou 
      510405, China.
LA  - chi
PT  - Journal Article
PT  - Meta-Analysis
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese 
      materia medica
JID - 8913656
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Tablets)
RN  - 0 (jinqi jiantang)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - *Insulin Resistance
MH  - Tablets
OTO - NOTNLM
OT  - Jinqi Jiangtang Tablets
OT  - Meta-analysis
OT  - insulin resistance
OT  - type 2 diabetes
EDAT- 2020/04/03 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
AID - 10.19540/j.cnki.cjcmm.20190401.502 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2020 Jan;45(1):188-195. doi: 
      10.19540/j.cnki.cjcmm.20190401.502.